Researchers at the Medical University of South Carolina's (MUSC) Foundation for Research Development (FRD) said recently that it piled up a record 69 patents during fiscal year 2015, more than doubling their 33 patents registered in fiscal year 2014.
Many of the patents pertain to therapies for spinal-cord and brain injuries, as well as cancer and leg ulcers.
“To have so many technologies successfully go through such rigorous review, both domestically and abroad, speaks to the novelty of the technologies that are being created at MUSC,” Jesse Goodwin, who is both deputy director for FRD and technology development officer for MUSC's South Carolina Clinical and Translational Research Institute (SCTR) said. “The fact that the patents are being nationalized into so many countries speaks to the importance of the technologies.”
The department focuses on cultivating ideas that have commercial potential for MUSC. By making patents for MUSC, the public's health also benefits when these ideas are available on the market. This is why the department usually licenses technologies through medical companies, making significant investments in the clinical and patent-development process to benefit the medical community and, by extension, the public.